Clinical scale Alimentiv operates as a leading GI CRO with a global footprint across 60+ countries and 5,000+ sites, presenting a scalable partner for multinational pharma and biotech clients seeking expansive trial activation and patient enrollment capabilities.

IBD leadership Trusted by partners for over 70% of all IBD compounds in development, Alimentiv offers end-to-end GI focused services including advanced imaging, precision medicine and histopathology, positioning it as a specialized accelerator for IBD programs.

AI enabled Recent integrations and partnerships with AI and imaging platforms (DYNAMIKA AI, CDS scoring, AI histology endpoints) indicate a strong selling point for efficiency, data quality, and novel endpoint modernization in clinical trials.

Rapid expansion Strategic collaborations and speaking engagements around DDW and UEG Week, plus new alliances with Pathways GI and imaging groups, signal ongoing growth, potential for co-development opportunities and expanded service scopes.

Financial readiness With revenue in the range of 100M to 250M and a robust CRO platform, Alimentiv presents an attractive target for deeper strategic partnerships, preferred vendor status, and expanded service packages to mid-to-large biopharma portfolios.